| 2BSM | A: | NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN |
| 2BT0 | A:; B: | NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED DESIGN |
| 2BYH | A: | 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4-CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE |
| 2BYI | A: | 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4-CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR CHAPERONE |
| 2BZ5 | A:; B: | STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF HSP90 INHIBITORS |
| 2CCS | A: | HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-3-YL)-BENZENE-1,2-DIOL |
| 2CCT | A: | HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)-4-PIPERAZIN-1-YL-2H-PYRAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE |
| 2CCU | A: | HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4-METHANESULPHONYL-BENZYL)-PIERAZIN-1-YL)-1H-PYRAZOL-3-YL)-BENZENE-1,3-DIOL |
| 2JJC | A: | HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE FRAGMENT |
| 2UWD | A: | INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO AND IN VIVO BY NOVEL, SYNTHETIC, POTENT RESORCINYLIC PYRAZOLE, ISOXAZOLE AMIDE ANALOGS |
| 2VCI | A: | 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
| 2VCJ | A: | 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
| 2WI1 | A: | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI2 | A:; B: | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI3 | A: | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI4 | A: | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI5 | A: | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI6 | A: | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2WI7 | A: | ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE HSP90 CHAPERONE |
| 2XAB | A:; B: | STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND |
| 2XDK | A: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XDL | A: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XDS | A: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XDU | A: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XDX | A: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XHR | A: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XHT | A: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XHX | A: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XJG | A: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XJJ | A:; B: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XJX | A: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2XK2 | A: | STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND |
| 2YE2 | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE3 | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE4 | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE5 | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE6 | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE7 | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE8 | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YE9 | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEA | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEB | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEC | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YED | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEE | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEF | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEG | A:; B: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEH | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEI | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YEJ | A: | HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL SCREENING |
| 2YI0 | A: | STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED-2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. |
| 2YI5 | A: | STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED-2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. |
| 2YI6 | A: | STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED-2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. |
| 2YI7 | A: | STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED-2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. |
| 3B24 | A:; B: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH AN AMINOTRIAZINE FRAGMENT MOLECULE |
| 3B25 | A: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH AN INHIBITOR CH4675194 |
| 3B26 | A:; B: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH AN INHIBITOR RO1127850 |
| 3B27 | A: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH AN INHIBITOR RO4919127 |
| 3B28 | A:; B: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH AN INHIBITOR CH5015765 |
| 3D0B | A: | CRYSTAL STRUCTURE OF BENZAMIDE TETRAHYDRO-4H-CARBAZOL-4-ONE BOUND TO HSP90 |
| 3HEK | A:; B: | HSP90 N-TERMINAL DOMAIN IN COMPLEX WITH 1-{4-[(2R)-1-(5-CHLORO-2,4-DIHYDROXYBENZOYL)PYRROLIDIN-2-YL]BENZYL}-3,3-DIFLUOROPYRROLIDINIUM |
| 3HHU | A:; B: | HUMAN HEAT-SHOCK PROTEIN 90 (HSP90) IN COMPLEX WITH {4-[3-(2,4-DIHYDROXY-5-ISOPROPYL-PHENYL)-5-THIOXO- 1,5-DIHYDRO-[1,2,4]TRIAZOL-4-YL]-BENZYL}-CARBAMIC ACID ETHYL ESTER {ZK 2819} |
| 3HYY | A: | CRYSTAL STRUCTURE OF HSP90 WITH FRAGMENT 37-D04 |
| 3HYZ | A:; B: | CRYSTAL STRUCTURE OF HSP90 WITH FRAGMENT 42-C03 |
| 3HZ1 | A: | CRYSTAL STRUCTURE OF HSP90 WITH FRAGMENTS 37-D04 AND 42-C03 |
| 3HZ5 | A: | CRYSTAL STRUCTURE OF HSP90 WITH FRAGMENT Z064 |
| 3K97 | A: | HSP90 N-TERMINAL DOMAIN IN COMPLEX WITH 4-CHLORO-6-{[(2R)-2-(2-METHYLPHENYL)PYRROLIDIN-1-YL]CARBONYL}BENZENE-1,3-DIOL |
| 3MNR | P: | CRYSTAL STRUCTURE OF BENZAMIDE SNX-1321 BOUND TO HSP90 |
| 3NMQ | A: | HSP90B N-TERMINAL DOMAIN IN COMPLEX WITH EC44, A PYRROLO-PYRIMIDINE METHOXYPYRIDINE INHIBITOR |
| 3O0I | A: | STRUCTURE OF THE HUMAN HSP90-ALPHA N-DOMAIN BOUND TO THE HSP90 INHIBITOR PU-H54 |
| 3QTF | A: | DESIGN AND SAR OF MACROCYCLIC HSP90 INHIBITORS WITH INCREASED METABOLIC STABILITY AND POTENT CELL-PROLIFERATION ACTIVITY |
| 3R91 | A: | MACROCYCLIC LACTAMS AS POTENT HSP90 INHIBITORS WITH EXCELLENT TUMOR EXPOSURE AND EXTENDED BIOMARKER ACTIVITY. |
| 3R92 | A: | DISCOVERY OF A MACROCYCLIC O-AMINOBENZAMIDE HSP90 INHIBITOR WITH HETEROCYCLIC TETHER THAT SHOWS EXTENDED BIOMARKER ACTIVITY AND IN VIVO EFFICACY IN A MOUSE XENOGRAFT MODEL. |
| 3RKZ | A: | DISCOVERY OF A STABLE MACROCYCLIC O-AMINOBENZAMIDE HSP90 INHIBITOR CAPABLE OF SIGNIFICANTLY DECREASING TUMOR VOLUME IN A MOUSE XENOGRAFT MODEL. |
| 3T0H | A: | STRUCTURE INSIGHTS INTO MECHANISMS OF ATP HYDROLYSIS AND THE ACTIVATION OF HUMAN HSP90 |
| 3T0Z | A: | HSP90 N-TERMINAL DOMAIN BOUND TO ATP |
| 3T10 | A: | HSP90 N-TERMINAL DOMAIN BOUND TO ACP |
| 3T1K | A:; B: | HSP90 N-TERMINAL DOMAIN BOUND TO ANP |
| 3T2S | A:; B: | HSP90 N-TERMINAL DOMAIN BOUND TO AGS |
| 3VHA | A: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR |
| 3VHC | A: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR |
| 3VHD | A:; B: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR, CH5164840 |
| 3WHA | A:; B: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH A TRICYCLIC INHIBITOR |
| 4AWO | A:; B: | COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED INHIBITORS |
| 4AWP | A:; B: | COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED INHIBITORS |
| 4AWQ | A:; B: | COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED INHIBITORS |
| 4B7P | A: | STRUCTURE OF HSP90 WITH NMS-E973 INHIBITOR BOUND |
| 4BQG | A: | STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND |
| 4BQJ | A: | STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND |
| 4EEH | A: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH AN INHIBITOR 3-(4-HYDROXY-PHENYL)-1H-INDAZOL-6-OL |
| 4EFT | A: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH AN INHIBITOR 3-CYCLOHEXYL-2-(6-HYDROXY-1H-INDAZOL-3-YL)-PROPIONITRILE |
| 4EFU | A: | HSP90 ALPHA N-TERMINAL DOMAIN IN COMPLEX WITH AN INHIBITOR 6-HYDROXY-3-(3-METHYL-BENZYL)-1H-INDAZOLE-5-CARBOXYLIC ACID BENZYL-METHYL-AMIDE |
| 4HY6 | A: | CRYSTAL STRUCTURE OF THE HUMAN HSP90-ALPHA N-DOMAIN BOUND TO THE HSP90 INHIBITOR FJ1 |
| 4NH9 | A: | CORRELATION BETWEEN CHEMOTYPE-DEPENDENT BINDING CONFORMATIONS OF HSP90 ALPHA/BETA AND ISOFORM SELECTIVITY |
)
)